Chemoresistance mechanisms of breast cancer and their countermeasures

Harbeck, 2017, Breast cancer, Lancet, 389, 1134, 10.1016/S0140-6736(16)31891-8

Kang, 2004, Epithelial-mesenchymal transitions: twist in development and metastasis, Cell, 118, 277, 10.1016/j.cell.2004.07.011

Lo, 2007, Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelial-mesenchymal transition in cancer cells via up-regulation of TWIST gene expression, Cancer Res., 67, 9066, 10.1158/0008-5472.CAN-07-0575

Pham, 2007, Upregulation of Twist-1 by NF- B blocks cytotoxicity induced by chemotherapeutic drugs, Mol. Cell. Biol., 27, 3920, 10.1128/MCB.01219-06

Vesuna, 2011, Twist contributes to hormone resistance in breast cancer by downregulating estrogen receptor-α, Oncogene, 31, 3223, 10.1038/onc.2011.483

Fruci, 2016, Multiple drug resistance in pediatric solid tumors, Curr. Drug Metab., 17, 308, 10.2174/1567205010666131212110948

Borst, 2000, A family of drug transporters: the multidrug resistance-associated proteins, J. Natl. Cancer Inst., 92, 1295, 10.1093/jnci/92.16.1295

Sodani, 2012, Multidrug resistance associated proteins in multidrug resistance, Chin. J. Cancer, 31, 58, 10.5732/cjc.011.10329

Levin, 2014, Extranuclear estrogen receptor’s roles in physiology: lessons from mouse models, Am. J. Physiol. Endocrinol. Metab., 307, E133, 10.1152/ajpendo.00626.2013

Huang, 2011, Nuclear translocation of epidermal growth factor receptor by akt-dependent phosphorylation enhances breast cancer-resistant protein expression in gefitinib-resistant cells, J. Biol. Chem., 286, 20558, 10.1074/jbc.M111.240796

Jackson, 2009, The DNA-damage response in human biology and disease, Nature, 461, 1071, 10.1038/nature08467

Nikitaki, 2015, Molecular inhibitors of DNA repair: searching for the ultimate tumor killing weapon, Future Med. Chem., 7, 1543, 10.4155/fmc.15.95

Marteijn, 2014, Understanding nucleotide excision repair and its roles in cancer and ageing, Nat. Rev. Mol. Cell Biol., 15, 465, 10.1038/nrm3822

Krokan, 2013, Base excision repair, Cold Spring Harb. Perspect. Biol., 5, 10.1101/cshperspect.a012583

Prakash, 2015, Homologous recombination and human health: the roles of BRCA1, BRCA2, and associated proteins, Cold Spring Harb. Perspect. Biol., 7, 10.1101/cshperspect.a016600

Martin, 2018, Double strand break DNA repair occurs via non-homologous end-joining in mouse MII oocytes, Sci. Rep., 8, 10.1038/s41598-018-27892-2

Li, 2012, Cisplatin regulates the MAPK kinase pathway to induce increased expression of DNA repair gene ERCC1 and increase melanoma chemoresistance, Oncogene, 31, 2412, 10.1038/onc.2011.426

Zhao, 2016, MiR-770-5p inhibits cisplatin chemoresistance in human ovarian cancer by targeting ERCC2, Oncotarget, 7, 53254, 10.18632/oncotarget.10736

Altan, 2016, High expression of MRE11-RAD50-NBS1 is associated with poor prognosis and chemoresistance in gastric Cancer, Anticancer Res., 36, 5237, 10.21873/anticanres.11094

Silva, 2010, Breast cancer risk and common single nucleotide polymorphisms in homologous recombination DNA repair pathway genes XRCC2, XRCC3, NBS1 and RAD51, Cancer Epidemiol., 34, 85, 10.1016/j.canep.2009.11.002

Kovalchuk, 2008, Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin, Mol. Cancer Ther., 7, 2152, 10.1158/1535-7163.MCT-08-0021

Liang, 2010, Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1, Biochem. Pharmacol., 79, 817, 10.1016/j.bcp.2009.10.017

He, 2013, miR-342 is associated with estrogen receptor-α expression and response to tamoxifen in breast cancer, Exp. Ther. Med., 5, 813, 10.3892/etm.2013.915

Muluhngwi, 2015, Roles for miRNAs in endocrine resistance in breast cancer, Endocr. Relat. Cancer, 22, R279, 10.1530/ERC-15-0355

Cochrane, 2009, MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents, Mol. Cancer Ther., 8, 1055, 10.1158/1535-7163.MCT-08-1046

Zhou, 2010, MicroRNA-125b confers the resistance of breast Cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression, J. Biol. Chem., 285, 21496, 10.1074/jbc.M109.083337

Pavlopoulou, 2016, Determinants of resistance to chemotherapy and ionizing radiation in breast cancer stem cells, Cancer Lett., 380, 485, 10.1016/j.canlet.2016.07.018

Zhou, 2016, Nilotinib reverses ABCB1/P-glycoprotein-mediated multidrug resistance but increases cardiotoxicity of doxorubicin in a MDR xenograft model, Toxicol. Lett., 259, 124, 10.1016/j.toxlet.2016.07.710

Tanei, 2009, Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers, Clin. Cancer Res., 15, 4234, 10.1158/1078-0432.CCR-08-1479

Morschhauser, 2007, Phase I/II trial of a P-glycoprotein inhibitor, Zosuquidar.3HCl trihydrochloride (LY335979), given orally in combination with the CHOP regimen in patients with non-Hodgkin’s lymphoma, Leuk. Lymphoma, 48, 708, 10.1080/10428190701190169

Collina, 2015, Prognostic value of Cancer stem cells markers in triple-negative breast Cancer, Biomed Res. Int., 2015, 1, 10.1155/2015/158682

Pinto, 2013, Breast cancer stem cells and epithelial mesenchymal plasticity - Implications for chemoresistance, Cancer Lett., 341, 56, 10.1016/j.canlet.2013.06.003

Liu, 2013, Breast cancer stem cells transition between epithelial and mesenchymal states reflective of their normal counterparts, Stem Cell Rep., 2, 78, 10.1016/j.stemcr.2013.11.009

Dandawate, 2016, Targeting cancer stem cells and signaling pathways by phytochemicals: novel approach for breast cancer therapy, Semin. Cancer Biol., 40–41, 192, 10.1016/j.semcancer.2016.09.001

Hazarika, 2017, U.S. FDA approval summary: nivolumab for treatment of unresectable or metastatic melanoma following progression on ipilimumab, Clin. Cancer Res., 23, 3484, 10.1158/1078-0432.CCR-16-0712

Borrie, 2017, Cognitive dysfunctions in intellectual disabilities: the contributions of the Ras-MAPK and PI3K-AKT-mTOR pathways, Annu. Rev. Genomics Hum. Genet., 18, 115, 10.1146/annurev-genom-091416-035332

Sharma, 2017, Primary, adaptive, and acquired resistance to cancer immunotherapy, Cell, 168, 707, 10.1016/j.cell.2017.01.017

Al-Harras, 2016, Polymorphisms of glutathione S-transferase π 1 and toll-like receptors 2 and 9: association with breast cancer susceptibility, Oncol. Lett., 11, 2182, 10.3892/ol.2016.4159

Fan, 2014, Breast cancer in China, Lancet Oncol., 15, e279, 10.1016/S1470-2045(13)70567-9

Gatenby, 2010, Evolutionary dynamics of cancer prevention, Nat. Rev. Cancer, 10, 526, 10.1038/nrc2892

Nathanson, 2014, Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA, Science, 343, 72, 10.1126/science.1241328

Li, 2006, Tumor microenvironment and drug resistance in hematologic malignancies, Blood Rev., 20, 333, 10.1016/j.blre.2005.08.003

Shannon, 2003, Tumour hypoxia, chemotherapeutic resistance and hypoxia-related therapies, Cancer Treat. Rev., 29, 297, 10.1016/S0305-7372(03)00003-3

Tsuruo, 2003, Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal, Cancer Sci., 94, 15, 10.1111/j.1349-7006.2003.tb01345.x

Xu, 2005, Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia, Cancer Res., 65, 613, 10.1158/0008-5472.613.65.2

Vannini, 2008, Role of p53 codon 72 arginine allele in cell survival in vitro and in the clinical outcome of patients with advanced breast cancer, Tumour Biol., 29, 145, 10.1159/000143400

Martin, 2008, Hypoxia-inducible Factor-2α transactivates Abcg2 and promotes cytoprotection in cardiac side population cells, Circ. Res., 102, 1075, 10.1161/CIRCRESAHA.107.161729

Estrella, 2013, Acidity generated by the tumor microenvironment drives local invasion, Cancer Res., 73, 1524, 10.1158/0008-5472.CAN-12-2796

Qi, 2007, The vacuolar (H+)-ATPase: subunit arrangement and in vivo regulation, J. Bioenerg. Biomembr., 39, 423, 10.1007/s10863-007-9116-8

Fogarty, 2014, HRG-1 enhances cancer cell invasive potential and couples glucose metabolism to cytosolic/extracellular pH gradient regulation by the vacuolar-H(+) ATPase, Oncogene, 33, 4653, 10.1038/onc.2013.403

Lozupone, 2015, TM9SF4 is a novel V-ATPase-interacting protein that modulates tumor pH alterations associated with drug resistance and invasiveness of colon cancer cells, Oncogene, 34, 5163, 10.1038/onc.2014.437

Boelens, 2014, Exosome transfer from stromal to breast cancer cells regulates therapy resistance pathways, Cell, 159, 499, 10.1016/j.cell.2014.09.051

Huang, 2017, Downregulation of estrogen receptor and modulation of growth of breast cancer cell lines mediated by paracrine stromal cell signals, Breast Cancer Res. Treat., 161, 229, 10.1007/s10549-016-4052-0

Ansell, 2013, Cellular composition of the tumor microenvironment, Am. Soc. Clin. Oncol. Educ. Book, 33, e91, 10.14694/EdBook_AM.2013.33.e91

De Palma, 2011, Cancer: macrophages limit chemotherapy, Nature, 472, 303, 10.1038/472303a

Shree, 2011, Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer, Genes Dev., 25, 2465, 10.1101/gad.180331.111

DeNardo, 2011, Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy, Cancer Discov., 1, 54, 10.1158/2159-8274.CD-10-0028

Mitchem, 2013, Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses, Cancer Res., 73, 1128, 10.1158/0008-5472.CAN-12-2731

Patel, 2010, Mesenchymal stem cells protect breast Cancer cells through regulatory t cells: role of mesenchymal stem cell-derived TGF-β, J. Immunol., 184, 5885, 10.4049/jimmunol.0903143

Bonomi, 2015, Human amniotic mesenchymal stromal cells (hAMSCs) as potential vehicles for drug delivery in cancer therapy: an in vitro study, Stem Cell Res. Ther., 6, 155, 10.1186/s13287-015-0140-z

Virrey, 2008, Stress chaperone GRP78/BiP confers chemoresistance to tumor-associated endothelial cells, Mol. Cancer Res., 6, 1268, 10.1158/1541-7786.MCR-08-0060

Virrey, 2008, Increased survivin expression confers chemoresistance to tumor-associated endothelial cells, Am. J. Pathol., 173, 575, 10.2353/ajpath.2008.071079

Alavi, 2007, Chemoresistance of endothelial cells induced by basic fibroblast growth factor depends on Raf-1-mediated inhibition of the proapoptotic kinase, ASK1, Cancer Res., 67, 2766, 10.1158/0008-5472.CAN-06-3648

Chaiwun, 2011, GSTPi-positive tumour microenvironment-associated fibroblasts are significantly associated with GSTPi-negative cancer cells in paired cases of primary invasive breast cancer and axillary lymph node metastases, Br. J. Cancer, 105, 1224, 10.1038/bjc.2011.352

Evseenko, 2007, Independent regulation of apical and basolateral drug transporter expression and function in placental trophoblasts by cytokines, steroids, and growth factors, Drug Metab. Dispos., 35, 595, 10.1124/dmd.106.011478

Hartz, 2010, Estrogen receptor signaling through phosphatase and tensin homolog/phosphoinositide 3-kinase/akt/glycogen synthase kinase 3 down-regulates blood-brain barrier breast cancer resistance protein, J. Pharmacol. Exp. Ther., 334, 467, 10.1124/jpet.110.168930

Ehata, 2010, Transforming growth factor-β decreases the cancer-initiating cell population within diffuse-type gastric carcinoma cells, Oncogene, 30, 1693, 10.1038/onc.2010.546

Zhang, 2011, Up-regulation of breast cancer resistance protein plays a role in HER2-mediated chemoresistance through PI3K/Akt and nuclear factor-kappa B signaling pathways in MCF7 breast cancer cells, Acta Biochim. Biophys. Sin. (Shanghai), 43, 647, 10.1093/abbs/gmr050

Kang, 2005, Cyclooxygenase-independent down-regulation of multidrug resistance-associated protein-1 expression by celecoxib in human lung cancer cells, Mol. Cancer Ther., 4, 1358, 10.1158/1535-7163.MCT-05-0139

Pérez-Tomás, 2006, Multidrug resistance: retrospect and prospects in anti-cancer drug treatment, Curr. Med. Chem., 13, 1859, 10.2174/092986706777585077

Tan, 2013, Identification of novel dietary phytochemicals inhibiting the efflux transporter breast cancer resistance protein (BCRP/ABCG2), Food Chem., 138, 2267, 10.1016/j.foodchem.2012.12.021

Mubashar, 2004, Differential effects of toremifene on doxorubicin, vinblastine and Tc-99m-sestamibi in P-glycoprotein-expressing breast and head and neck cancer cell lines, Acta Oncol., 43, 443, 10.1080/02841860410031048

Ma, 2008, Lobeline, a piperidine alkaloid from Lobelia can reverse P-gp dependent multidrug resistance in tumor cells, Phytomedicine, 15, 754, 10.1016/j.phymed.2007.11.028

Diesendruck, 2017, Novel immune check point inhibiting antibodies in cancer therapy—opportunities and challenges, Drug Resist. Updates, 30, 39, 10.1016/j.drup.2017.02.001

Bachelot, 2012, Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study, J. Clin. Oncol., 30, 2718, 10.1200/JCO.2011.39.0708

Martín, 2013, Melatonin-induced methylation of the ABCG2/BCRP promoter as a novel mechanism to overcome multidrug resistance in brain tumour stem cells, Br. J. Cancer, 108, 2005, 10.1038/bjc.2013.188

Kuo, 2009, Redox regulation of multidrug resistance in cancer chemotherapy: molecular mechanisms and therapeutic opportunities, Antioxid. Redox Signal., 11, 99, 10.1089/ars.2008.2095

Tang, 2017, Targeted multidrug delivery system to overcome chemoresistance in breast cancer, Int. J. Nanomed., 12, 671, 10.2147/IJN.S124770

Lv, 2016, Quercetin and doxorubicin co-encapsulated biotin receptor-targeting nanoparticles for minimizing drug resistance in breast cancer, Oncotarget, 7, 32184, 10.18632/oncotarget.8607

Zheng, 2016, Co-delivery of Se nanoparticles and pooled SiRNAs for overcoming drug resistance mediated by P-glycoprotein and class III β-tubulin in drug-resistant breast cancers, Acta Biomater., 31, 197, 10.1016/j.actbio.2015.11.041

Wang, 2014, Doxorubicin and lapatinib combination nanomedicine for treating resistant breast cancer, Mol. Pharm., 11, 2600, 10.1021/mp400687w

Liu, 2008, A potential target associated with both cancer and cancer stem cells: a combination therapy for eradication of breast cancer using vinorelbine stealthy liposomes plus parthenolide stealthy liposomes, J. Control. Release, 129, 18, 10.1016/j.jconrel.2008.03.022

Meng, 2013, Codelivery of an optimal Drug/siRNA combination using mesoporous silica nanoparticles to overcome drug resistance in breast Cancer in vitro and in vivo, ACS Nano, 7, 994, 10.1021/nn3044066

Tran, 2016, Enhancing activity of artesunate against breast cancer cells via induced-apoptosis pathway by loading into lipid carriers, Artif. Cells Nanomed. Biotechnol., 44, 1979, 10.3109/21691401.2015.1129616

Amaral, 2017, Immunotherapy in managing metastatic melanoma: which treatment when?, Expert Opin. Biol. Ther., 17, 1523, 10.1080/14712598.2017.1378640

Deng, 2018, CDK4/6 inhibition augments antitumor immunity by enhancing T-cell activation, Cancer Discov., 8, 216, 10.1158/2159-8290.CD-17-0915

Muraro, 2017, Local high-dose radiotherapy induces systemic immunomodulating effects of potential therapeutic relevance in oligometastatic breast cancer, Front. Immunol., 8, 10.3389/fimmu.2017.01476

Bottai, 2017, Progress in nonviral gene therapy for breast cancer and what comes next?, Expert Opin. Biol. Ther., 17, 595, 10.1080/14712598.2017.1305351

Liu, 2017, The application of estrogen receptor-1 mutations’ detection through circulating tumor DNA in breast cancer, Cancer Transl. Med., 3, 46, 10.4103/ctm.ctm_10_17

Ma, 2016, ctDNA dynamics: a novel indicator to track resistance in metastatic breast cancer treated with anti-HER2 therapy, Oncotarget., 7, 66020, 10.18632/oncotarget.11791

Jenkins, 2018, Mechanisms of resistance to immune checkpoint inhibitors, Br. J. Cancer, 118, 9, 10.1038/bjc.2017.434

Gajewski, 2013, Innate and adaptive immune cells in the tumor microenvironment, Nat. Immunol., 14, 1014, 10.1038/ni.2703